Amylyx Pharmaceuticals, Inc. (AMLX) Stock Forecast
AMLX analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.83 / 5 from 12 analysts
- Price target
- $43.00 average of analyst targets
- Upside to target
- +63.2% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.38
- 52-week range
- $11.38 – $39.66
AMLX analyst ratings
12 analystsNumber of analysts at each rating.
AMLX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AMLX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.37 | −$0.42 | −$0.31 | −$0.37 | −0.5% | 8 |
| Current fiscal year (2026) | −$1.48 | −$1.60 | −$1.26 | −$1.53 | +3.0% | 8 |
| Next fiscal year (2027) | −$1.09 | −$1.63 | $0.70 | −$1.48 | +26.5% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AMLX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $41,600 | $0 | $416,000 | 0.0% | 10 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 10 |
| Next fiscal year (2027) | $28.3M | $6.5M | $54.0M | 0.0% | 10 |
AMLX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AMLX revenue: reported and forecast
AMLX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.33 | −$0.36 | −$0.38 | −$0.38 | −$0.37 | +11.1% | 2 up · 4 down |
| Current fiscal year (2026) | −$1.38 | −$1.47 | −$1.50 | −$1.50 | −$1.48 | +7.2% | 2 up · 4 down |
| Next fiscal year (2027) | −$1.27 | −$1.38 | −$1.15 | −$1.15 | −$1.09 | −13.9% | 3 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AMLX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; AMLX beat in 5 of 12.
What analysts expect from AMLX
12 analysts cover Amylyx Pharmaceuticals; their consensus rating is strong buy (4.83 on a 1–5 scale, where 5 is a strong buy). The average price target is $43.00, 63.2% above the latest close of $26.34. Analysts expect earnings of −$1.48 per share for 2026, +3.0% from a year earlier. For 2027 the average estimate is −$1.09 per share on revenue of $28.3 million. Amylyx Pharmaceuticals beat the EPS estimate in 5 of the last 12 quarters.
Related: AMLX income statement, AMLX key metrics, AMLX chart. See the AMLX stock overview for the latest quote and news.
AMLX forecast FAQ
What is Amylyx Pharmaceuticals's price target?
The average analyst price target for Amylyx Pharmaceuticals is $43.00, 63.2% above the latest close of $26.34.
Is Amylyx Pharmaceuticals a buy, hold or sell?
Of 12 analysts covering Amylyx Pharmaceuticals, 11 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Amylyx Pharmaceuticals's EPS forecast?
Analysts forecast −$1.48 per share for 2026 (range −$1.60 to −$1.26); for 2027 the estimate is −$1.09.
When does Amylyx Pharmaceuticals report earnings?
Amylyx Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.38.
Does Amylyx Pharmaceuticals usually beat earnings estimates?
Amylyx Pharmaceuticals reported EPS at or above the analyst estimate in 5 of the last 12 quarters.